Agios Pharmaceuticals (NASDAQ:AGIO) Posts Quarterly Earnings Results, Misses Expectations By $0.05 EPS

Agios Pharmaceuticals (NASDAQ:AGIO) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.74) earnings per share for the quarter, missing the consensus estimate of ($1.69) by ($0.05), Zacks reports. Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ:AGIO opened at $33.75 on Friday. The company has a market cap of $1.93 billion, a P/E ratio of 2.98 and a beta of 0.88. Agios Pharmaceuticals has a 1 year low of $26.50 and a 1 year high of $62.58. The stock’s fifty day moving average price is $34.36 and its 200-day moving average price is $43.08.

Insider Activity

In other news, insider Tsveta Milanova sold 2,804 shares of the company’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $32.18, for a total transaction of $90,232.72. Following the transaction, the insider now directly owns 18,906 shares of the company’s stock, valued at $608,395.08. This represents a 12.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 4.93% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. StockNews.com lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 14th. Royal Bank of Canada boosted their target price on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a report on Tuesday, December 10th. Scotiabank boosted their target price on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a report on Monday, December 9th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $56.33.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.